证券代码：605388 证券简称：均瑶健康 公告编号：2025-025 湖北均瑶大健康饮品股份有限公司 关于控股股东部分股份解除质押 及部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）控股股东上海均 瑶（集团）有限公司（以下简称"均瑶集团"）持有公司股份总数为 196,632,002 股，占公司总股本的 32.75%。本次部分股份解除质押及质押后，均瑶集团累计 质押公司股份 150,800,000 股，占其所持公司股份总数的 76.69%，占公司总股本 的 25.11%。 ● 公司控股股东、实际控制人及其一致行动人持有公司股份 403,853,404 股， 占公司总股本的 67.25%。控股股东、实际控制人及其一致行动人累计质押股份 数量（含本次）合计 282,244,673 股，占其持股数量比例的 69.89%，占公司总股 本的 47.00%。 一、本次控股股东股份解除质押基本情况 公司于 2025 年 5 月 23 日收到公司控股股东 ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN H O N G K O N G PARIS MADRID S I L I C O N V A L L E Y 中国上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52341670 网址/Website:http://www.grandall.com.cn 国浩律师（上海）事务所 关于湖北均瑶大健康饮品股份有限公司 2024 年年度股东大会的 法律意见书 致：湖北均瑶大健康饮品股份有限公司 根据《中华人民共和国公司法》（ ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-026 湖北均瑶大健康饮品股份有限公司 2024年年度股东大会决议公告 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 23 日 (二)股东大会召开的地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 209 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 412,735,402 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 70.4538 | 本次股东大会由湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董事 会召集，本次会议现场由董事长王均豪先生主持，采用现场与网络投票 ...

湖北均瑶大健康饮品股份有限公司 二〇二四年年度股东大会会议资料 湖北均瑶大健康饮品股份有限公司 二〇二四年年度股东大会 会议资料 湖北均瑶大健康饮品股份有限公司 二〇二四年年度股东大会会议资料 目 录 | 会议须知 | | 3 | | --- | --- | --- | | 会议议程 | | 5 | | 议案一：关于 2024 年度董事会工作报告的议案 7 | | | | 议案二：关于 2024 年度监事会工作报告的议案 8 | | | | 议案三：关于 2024 年度财务决算报告的议案 9 | | | | 议案四：关于 年度利润分配预案的议案 10 | 2024 | | | 议案五：关于公司 2024 年年度报告及摘要的议案 11 | | | | 议案六：关于确认公司董事及监事 2024 年度薪酬的议案 12 | | | | 议案七：关于预计公司 2025 年日常关联交易的议案 13 | | | | 议案八：关于使用部分闲置自有资金进行现金管理暨关联交易的议案 14 | | | | 议案九：关于使用部分自有资金开展金融服务业务暨关联交易的议案 15 | | | 2 湖北均瑶大健康饮品股份有限公司 二〇二四年 ...

Core Insights - The dairy industry is experiencing a significant downturn, with 19 listed dairy companies in A-shares reporting a total revenue of 184.83 billion yuan in 2023, a year-on-year decrease of 7.44% [1] - The total net profit attributable to shareholders dropped from 13.10 billion yuan to 9.58 billion yuan, with 13 companies reporting a decline in net profit [1] - Key factors affecting the industry include oversupply, weakened demand, and high inventory levels, leading to a continuous decline in fresh milk prices and intensified competition [1] Revenue and Profit Trends - In 2023, 14 out of 19 dairy companies saw a decline in revenue, compared to only 6 the previous year [1] - The dairy industry index has fallen over 50% from its peak in January 2021 to its low in September 2024, although a noticeable increase has been observed since September 2024 [1] - The expectation is that upstream destocking will help stabilize fresh milk prices, alongside policies aimed at boosting demand [1] Sales and Management Expenses - Total sales expenses for the 19 listed dairy companies amounted to 31.55 billion yuan, a decrease of 2.96% year-on-year, which is less than the revenue decline [2] - The median sales expense ratio increased from 11.49% to 13.05%, with only 6 companies reporting a decrease in their sales expense ratios [2] - Companies like Beiyinmei had the highest sales expense ratio at 26.42%, followed by Miaokelando at 19.03% and Yili at 18.99% [2] Management Expenses - Total management expenses for the 19 listed dairy companies were 7.58 billion yuan, a year-on-year decrease of 9.06% [3] - Eight companies reported an increase in management expenses, with Miaokelando showing the highest growth at 81.43% [3] - The median management expense ratio rose from 5.82% to 6.55%, indicating that 11 companies experienced an increase in their management expense ratios [3]

Group 1: Lactobacillus Business Trends - The company positions its lactobacillus business within the broader health beverage framework, moving beyond a single category focus [1] - The lactobacillus beverage segment has seen a decline due to insufficient innovation compared to the overall beverage industry [1] - Sales performance for the lactobacillus business is expected to show slight growth in 2024, driven by increased orders during the Spring Festival, but will be impacted by the absence of this effect in Q1 2025 [1] Group 2: International Expansion and Probiotics Business - The company's overseas operations have shown strong performance, with a 77% year-on-year increase in overseas revenue in Q1 2025 [2] - Significant growth in orders from major U.S. clients reflects the company's long-term strategy of nurturing relationships through technical communication [2] - The company avoids competing in the low-end domestic market, focusing instead on establishing long-term technical collaborations with professional clients [2] Group 3: E-commerce and Brand Performance - The "Daily Doctor" brand has achieved profitability through precise product positioning and market strategy in the functional probiotics segment [3] - The company minimizes reliance on influencer marketing, using it as a supplementary method rather than a core revenue source [3] - The shift towards activating owned brand traffic indicates a growing consumer recognition and repurchase intention for "Daily Doctor" [3]

Group 1: Plant-Based Beverage Industry - The plant-based beverage industry is experiencing a divergence in performance among major companies, with some like Yangyuan Beverage seeing profit growth despite a slight revenue decline, while others like Huanlejia face declines in both revenue and profit [2] - Traditional plant-based beverages are limited by seasonal demand and face competition from emerging categories, necessitating innovation to meet the health-conscious preferences of younger consumers [2] Group 2: Chinese Condiment Industry - The Chinese condiment industry has evolved from a focus on export during the planned economy era to becoming a global rule-maker, with companies like Haitian Flavoring and Lee Kum Kee leading the way [3][4] - The industry is leveraging cultural exports and technological innovation to reshape its landscape, emphasizing quality and innovation to support the globalization of Chinese flavors [4] Group 3: Community Supermarkets - Community supermarkets are gaining traction, with brands like Ole' and Hema NB expanding rapidly, focusing on middle-class consumers and enhancing product quality and efficiency [5] - The core competitiveness of community supermarkets lies in product control and operational efficiency, requiring deep supply chain engagement and digital tool application [5] Group 4: Health and Wellness Trends - There is a growing trend among young consumers towards "light wellness" products, with a focus on health-conscious beverages that are low in sugar and calories [6] - Boxed water products have seen significant sales growth, with products like fig and flaxseed water experiencing a 130% increase in sales [6] Group 5: Instant Food Market - The instant food market is shifting from high-end products to a focus on affordability, with budget products now accounting for nearly 50% of the instant noodle market [7] - Future opportunities lie in diversifying flavors and adjusting strategies to meet the differentiated demands of various market segments [7] Group 6: Aging Population and Bakery Market - The aging population is driving demand for soft-textured baked goods, with health-oriented and age-appropriate products becoming market hotspots [9] - Innovations inspired by Japanese practices, such as low-sugar and low-salt options, are key directions for the industry [9] Group 7: Snack Food Market Forecast - The Chinese snack food market is projected to grow to 972 billion yuan by 2025, with nut snacks holding the largest market share [10] - The industry is witnessing a shift towards health-oriented ready-to-eat products, with e-commerce and live streaming becoming significant growth drivers [10] Group 8: Beverage Market Dynamics - The beverage market is undergoing adjustments, with significant growth in electrolyte water and tea beverages, while packaged water sales are declining [12] - Companies like Nongfu Spring and Eastroc Beverage are experiencing contrasting performance, highlighting the competitive landscape [12] Group 9: Pre-made Dishes Market - The pre-made dishes market is experiencing a cooling phase, with many leading companies facing revenue declines due to changing consumer demands and increased competition [14] - Opportunities remain in local specialties and high-end products, with new retail channels emerging as growth points [14] Group 10: Health Drink Innovations - The market for Chinese herbal health drinks is expanding rapidly, with sales increasing from 0.1 billion yuan in 2018 to an expected 10 billion yuan by 2028 [19] - Companies are focusing on packaging, formulation, and marketing to differentiate themselves in a competitive landscape [19] Group 11: Functional Beverage Market - The functional beverage market is becoming increasingly diverse, with brands like Zhenguanzhuang entering the market with zero-sugar options targeting health-conscious consumers [32] - The collaboration between Zhenguanzhuang and Super Extreme Drink aims to fill market gaps and cater to the preferences of the younger generation [32] Group 12: Snack Food IPO Trends - Recent trends show a surge in snack food companies seeking IPOs in Hong Kong, with brands like Three Squirrels aiming to solidify their market position [21] - These companies face challenges related to competition and growth bottlenecks, despite their ambitions for expansion [21]

湖北均瑶大健康饮品股份有限公司 关于独立董事任期届满辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605388 证券简称：均瑶健康 公告编号：2025-024 特此公告。 湖北均瑶大健康饮品股份有限公司董事会 1 2025 年 5 月 10 日 2 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董事会近日收到独 立董事史占中先生的书面辞呈。根据《上市公司独立董事管理办法》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作》有关规定，独立董事在上市 公司连续任职时间不得超过六年。史占中先生因在公司连续担任独立董事期限已 满六年，现申请辞去公司独立董事、薪酬与考核委员会主任委员、提名委员会委 员的职务，辞任生效后将不在公司担任任何职务。 史占中先生的辞任将导致公司独立董事人数占董事会成员的比例低于三分 之一，根据《上市公司独立董事管理办法》等相关规定，其辞呈将自公司股东大 会选举产生新任独立董事之日起生效。在此之前，为保证公司董事会的正常运作， 将按照相关法律法规及《公司章程》规定继续履职。公 ...

Core Viewpoint - Junyao Health reported a significant decline in both revenue and net profit for the fiscal year 2024, indicating potential challenges in its operational performance [1][3]. Financial Performance Summary - For the year 2024, the company achieved operating revenue of 1.458 billion yuan, a decrease of 10.77% compared to the previous year [1][3]. - The net profit attributable to shareholders was -29.12 million yuan, down 150.57% from 57.58 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -57.99 million yuan, a decline of 287.62% from 30.91 million yuan in the previous year [1][3]. - The net cash flow from operating activities was 32.65 million yuan, a decrease of 61.95% year-on-year [1][3]. Q1 2025 Performance Summary - In the first quarter of 2025, the company reported operating revenue of 401.48 million yuan, an increase of 1.41% year-on-year [4][6]. - The net profit attributable to shareholders was 10.91 million yuan, a decrease of 58.29% compared to the same period last year [4][6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 7.03 million yuan, down 70.46% year-on-year [4][6]. - The net cash flow from operating activities was -97.06 million yuan, compared to -129.49 million yuan in the same period last year [4][6]. Dividend Distribution Plan - The company plans to distribute a cash dividend of 0.08 yuan per share (tax included) to all shareholders, totaling approximately 46.87 million yuan [1][3].

Core Viewpoint - Junyao Health has reported significant growth in its probiotic beverage and food business, positioning itself as a leader in the health industry with a focus on innovation and international expansion [1][2][6] Financial Performance - In 2024, Junyao Health achieved a revenue of 1.458 billion yuan, while the first quarter of 2025 saw revenue of 401 million yuan [1] - The probiotic beverage and food segment generated a total revenue of 792 million yuan in 2024, with a remarkable year-on-year growth of 139.19% in the first quarter of 2025 [2] Market Trends - The probiotic market in China is rapidly expanding, with a compound annual growth rate of 14% from 2018 to 2022, growing from 64.77 billion yuan to approximately 109.38 billion yuan [2] - Global probiotic industry value is expected to exceed 77 billion USD by 2025, with China accounting for over 25% of the market share [2] R&D and Innovation - Junyao Health emphasizes the importance of independent research and development, establishing a comprehensive "R&D-production-sales" integrated chain [2][3] - The subsidiary Junyao Runying has developed a resource library of over 30,000 probiotic strains and collaborates with several universities to enhance innovation [3] Supply Chain and Distribution - The company has expanded its e-commerce channels, achieving a staggering 1173.33% year-on-year growth in online sales in the first quarter of 2025 [2] - Junyao Health has established a comprehensive supply chain model, integrating raw materials, products, and distribution channels [3][4] International Expansion - In 2024, Junyao Health's international business generated approximately 84.6 million yuan, reflecting a year-on-year growth of 24.54%, with a 77.43% increase in the first quarter of 2025 [5] - Junyao Runying is recognized as a major probiotic production base in Asia, exporting to over 80 countries and regions [5] Policy and Market Outlook - The national initiative to promote "Weight Management Year" is expected to further boost the health industry, providing a favorable environment for Junyao Health's growth [6] - With its leading position in the ambient yogurt market and a comprehensive probiotic strategy, Junyao Health is well-positioned for sustained growth in the health industry [6]